Trial Profile

An Open-Label, Randomized Phase 2a Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Apr 2025 Results presented in the Caliway Biopharmaceuticals Media Release.
17 Apr 2025 According to a Caliway Biopharmaceuticals media release, company to present data from this study at the upcoming World Orphan Drug Congress USA 2025, to be held in Boston on April 24, 2025.
25 Apr 2024 According to a Caliway Biopharmaceuticals media release, U.S. FDA granted Orphan Drug Designation based on the CBL-0201DD Phase 2 study results for Dercum's disease in February 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com